4D Molecular Therapeutics (FDMT) Non Operating Income (2020 - 2026)
4D Molecular Therapeutics (FDMT) reported Non Operating Income of -$4000.0 for Q1 2026, down 105.97% year-over-year from $67000.0 in Q1 2025, and up 81.82% quarter-over-quarter from -$22000.0 in Q4 2025.
4D Molecular Therapeutics (FDMT) Non Operating Income (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 7 years of Non Operating Income data on file, last reported at -$4000.0 in Q1 2026.
- Non Operating Income for Q1 2026 came in at -$4000.0, down 105.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.1 million (changed N/A YoY), and the FY2025 annual result was -$37000.0, up 51.95% from the prior year.
- Non Operating Income grew to -$4000.0 in Q1 2026 per FDMT's latest filing, from -$22000.0 in the prior quarter.
- Over five years, Non Operating Income peaked at $5.7 million in Q1 2024 and troughed at -$1.2 million in Q4 2022.
- A 5-year average of $1.4 million and a median of $8500.0 in 2022 frame the typical range for Non Operating Income.
- The sharpest annual moves came in 2024 and 2025: Non Operating Income slumped 662.5% in 2024, then jumped 431000.0% in 2025.
- A 5-year view of Non Operating Income shows it stood at -$1.2 million in 2022, then surged by 454.63% to $4.4 million in 2023, then sank by 100.48% to -$21000.0 in 2024, then decreased by 4.76% to -$22000.0 in 2025, then soared by 81.82% to -$4000.0 in 2026.
- Business Quant data shows FDMT's Non Operating Income at -$4000.0 in Q1 2026, -$22000.0 in Q4 2025, and $4.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 444,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 9.35 Mn |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - | -4,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -4,000.00 |
| Dec 31, 2025 | -22,000.00 |
| Sep 30, 2025 | 4.31 Mn |
| Jun 30, 2025 | 4.80 Mn |
| Mar 31, 2025 | 67,000.00 |
| Dec 31, 2024 | -21,000.00 |
| Sep 30, 2024 | -1,000.00 |
| Jun 30, 2024 | -45,000.00 |
| Mar 31, 2024 | 5.74 Mn |
| Dec 31, 2023 | 4.37 Mn |
| Sep 30, 2023 | 3.72 Mn |
| Jun 30, 2023 | 8,000.00 |
| Mar 31, 2023 | -19,000.00 |
| Dec 31, 2022 | -1.23 Mn |
| Sep 30, 2022 | 9,000.00 |
| Mar 31, 2022 | 54,000.00 |
| Dec 31, 2021 | -319,000.00 |
| Sep 30, 2021 | -13,000.00 |
| Mar 31, 2021 | -94,000.00 |
| Dec 31, 2020 | -277,000.00 |